BENGALURU (Reuters) – Indian drugmaker Cadila Healthcare Ltd said on Monday it would seek local regulatory approval to treat COVID-19 patients with an already approved Hepatitis C drug, following promising interim results from a late-stage trial.
(Reporting by Sachin Ravikumar in Bengaluru; Editing by Shailesh Kuber)
